Key facts
- This page summarizes Michael John Sumner's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2022, 18:21.
Michael John Sumner - 30 Jun 2022 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- INO
- Reported as of
- 30 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2022, 18:21:27 UTC
- Prior SEC filing
- 06 Jul 2022
- Next SEC filing
- 28 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael John Sumner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael John Sumner filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 06 Jul 2022.
Change
- Previous filing in this sequence was filed on 06 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INO
transaction
Derivative
Common Stock Options
Award
- Transaction value
- $0
- Shares
- +160,000
- Change %
- Price
- $0.000000
- Shares after
- 160,000
- Date
- 30 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 160,000
- Exercise price
- $1.73
- Footnotes
- F1
INO
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +105,000
- Change %
- Price
- $0.000000
- Shares after
- 105,000
- Date
- 30 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 105,000
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The vesting schedule for the 160,000 options is as follows: 40,000 shares vested on June 30, 2022; 40,000 shares will vest on June 30, 2023; 40,000 shares will vest on June 30, 2024; 40,000 shares will vest on June 30, 2025.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.